Gold prices steady ahead of Fed decision; weekly weakness noted
RICHMOND, VA - Indivior PLC (NASDAQ/LSE:LON:INDV), a global pharmaceutical company specializing in the treatment of substance use disorders (SUD), has confirmed its participation in several investor events in June 2025. The company’s CEO, Joe Ciaffoni, and CFO, Ryan Preblick, will engage with investors through one-on-one and group meetings at the Jefferies Global Healthcare Conference in New York City on June 4th, the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 11th, and the Northland Growth Conference 2025, which will be held virtually on June 25th.
In addition to the meetings, CEO Joe Ciaffoni is set to partake in a fireside chat at the Jefferies conference, scheduled for 9:55 a.m. U.S. Eastern Time on June 4th. This discussion will be accessible to the public via a webcast link provided by the company.
Investors interested in scheduling meetings at these events are advised to contact representatives from Jefferies, Goldman Sachs, or Northland, respectively.
Indivior’s mission is to transform the treatment of SUD from a global crisis to a manageable chronic disease. The company, headquartered in Richmond, Virginia, operates in over 30 countries and employs more than 1,000 people worldwide. Indivior’s product portfolio focuses on opioid use disorder (OUD) treatments, and it is actively expanding its pipeline to offer a broader range of solutions for SUD.
This announcement is based on a press release statement provided by Indivior and reflects the company’s ongoing efforts to engage with the investment community and share its vision and developments in the field of SUD treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.